GlassScriptPhysician profile
Glenn M Little
NPI 1396727152
$1,098.46
in general payments reported to CMS, 2019-2025
12 companies · $79.25 in 2025
The $79.25 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $401 · 2024: $618 · 2025: $79.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,098.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $264.66 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $145.95 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $124.02 | 2023-2024 | |
| Lilly USA, LLC | $120.67 | 2023-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $101.76 | 2023-2024 | |
| Inspire Medical Systems, INC. | $90.02 | 2024 | Inspire |
| Lucid Diagnostics INC. | $82.47 | 2023 | |
| Astellas Pharma US INC | $46.15 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $45.89 | 2023 | Breztri, Airsupra |
| Amgen INC. | $42.32 | 2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $19.96 | 2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $14.59 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.